Printer Friendly

BIOSPECIFICS TECHNOLOGIES ISSUES STATEMENT ON OINTMENT SALES

 BIOSPECIFICS TECHNOLOGIES ISSUES STATEMENT ON OINTMENT SALES
 LYNBROOK, N.Y., Oct. 6 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC) today told a meeting of securities analysts that sales of the company's collagenase ointment with the trademark Santyl has been growing at the compound rate of 11 percent per month during this fiscal year. The rate of growth may increase as the company's licensee increases its sales force and because of additional awareness in the medical profession of Santyl's utility in treating deep second degree burns.
 Even with this rate of growth, sales have only reached approximately one percent of patients afflicted with bed sores -- one of the most important diseases of the elderly. The company anticipates reaching up to 25 percent of this market in the next few years making its topical collagenase treatment a "blockbuster" drug in the United States and abroad.
 -0- 10/6/92
 /CONTACT: Edwin Wegman, chairman of BioSpecifics Technologies, 516-593-7000, or Sam Witchel of Scharff, Witchel & Co., Inc., 212-983-1060, for BioSpecifics Technologies/
 (BSTC) CO: BioSpecifics Technologies Corp. ST: New York IN: HEA SU:


TS-SH -- NY033 -- 6997 10/06/92 10:53 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 6, 1992
Words:186
Previous Article:TELTECH NAMED TO PROVIDE TECHNOLOGY ACCESS SERVICES FOR MAINE PROGRAM
Next Article:BT FOCUSES MANAGEMENT ON CUSTOMERS' REQUIREMENTS FOR GLOBAL SERVICES; MAKES KEY CHANGES INCLUDING NORTH AMERICAN MANAGEMENT STRUCTURE
Topics:


Related Articles
BIOSPECIFICS ANNOUNCES EXPANSION OF CLINICAL TRIALS FOR OINTMENT
BIOSPECIFICS TECHNOLOGIES RECEIVES CLINICAL TRIAL EXEMPTION FOR COLLAGENASE OINTMENT IN ENGLAND
BIOSPECIFICS TECHNOLOGIES ANNOUNCES LICENSEE'S DOUBLING OF SALES
NEW STUDY AND EXPERT PANEL REPORT COLLAGENASE TREATMENT SIGNIFICANTLY MORE EFFECTIVE FOR BURNS AND PRESSURE ULCERS
BIOSPECIFICS TECHNOLOGIES CORP. ANNOUNCES APPROVAL OF COLLAGENASE SANTYL IN CANADA
BIOSPECIFICS TECHNOLOGIES CORP. LICENSEE RECEIVES MARKETING APPROVAL OF COLLAGENASE OINTMENT IN INDIA
BIOSPECIFICS TECHNOLOGIES CORP. ANNOUNCES COLLAGENASE OINTMENT CONTRACT IN ITALY
BIOSPECIFICS TECHNOLOGIES CORP. ANNOUNCES FOURTH QUARTER AND YEAR-END RESULTS FOR FISCAL 1995
BIOSPECIFICS TECHNOLOGIES CORP. ANNOUNCES SUCCESSFUL COMPLETION IN UNITED KINGDOM OF CLINICAL STUDY OF COLLAGENASE OINTMENT FOR TREATMENT OF PRESSURE...
BioSpecifics Technologies Corp. Notified by Nasdaq Listing Qualifications Panel That Its Shares Will Be Delisted; Trading to Start March 24, 2004 on...

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters